#news #biotech Apexigen, BMS to combine CD40 and anti-CSF-1 drugs with Opdivo in new study

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Apexigen, BMS to combine CD40 and anti-CSF-1 drugs with Opdivo in new study .Apexigen is collaborating with Yale Cancer Center on an early-stage clinical trial that combines the biotech’s APX005M CD40 activator with Bristol-Myers Squibb’s Opdivo and cabiralizumab, an investigational anti-CSF-1 antibody, in patients with advanced solid tumors.

from FierceBiotech: Biotech https://ift.tt/2y8qCt9